RxDoctor Payments Data

Diego de la Mora, MD

Internal Medicine · El Paso, TXNPI 1124349667

Payments from drug & device makers

$1,541in general payments, 2019–2025

Across 79 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$477
  • Lilly USA, LLC$184
  • Abbott$118
  • Exact Sciences$110
  • Boehringer Ingelheim$101
  • Pfizer$88
  • plus $462 from 11 others

What the payments were for

  • Food & beverage$1,541100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,541 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$26,071
Medicare patients
59
Services billed
368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin108$150,754
MounjaroTirzepatide103$135,028
FarxigaDapagliflozin Propanediol96$114,184
OzempicSemaglutide65$95,534
TrulicityDulaglutide59$93,726
RybelsusSemaglutide36$64,461
JanuviaSitagliptin Phosphate49$61,411
EliquisApixaban42$52,328
CreonLipase/Protease/Amylase18$33,526
JanumetSitagliptin Phos/Metformin Hcl22$30,849
ArexvyRsvpref3 Antigen/As01e/Pf86$26,488
Synjardy XrEmpagliflozin/Metformin Hcl18$22,815
MyrbetriqMirabegron21$22,336
ShingrixVaricella-Zoster Ge/As01b/Pf100$22,094
JubliaEfinaconazole14$20,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$184$228,754162 claims
Boehringer IngelheimJardiance, Synjardy Xr$101$173,569126 claims
Novo NordiskOzempic, Rybelsus$79$159,995101 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$477$133,063136 claims
MerckJanuvia, Janumet$49$92,26171 claims
GSKArexvy, Shingrix, Incruse Ellipta, Anoro Ellipta, Breo Ellipta$48$90,260266 claims
PfizerEliquis$88$52,32842 claims
AbbVieCreon$38$33,52618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →